I-Mab (IMAB)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 10:36AM EDT. Market open.
| Previous Close | 1.8100 |
| Open | 1.8000 |
| Bid | 1.2900 x 200 |
| Ask | 1.8100 x 100 |
| Day's Range | 1.7900 - 1.8100 |
| 52 Week Range | 1.1600 - 3.4500 |
| Volume | |
| Avg. Volume | 367,885 |
| Market Cap | 145.263M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
I-Mab ( NASDAQ:IMAB ) Full Year 2023 Results Key Financial Results Net loss: CN¥1.47b (loss narrowed by 39% from FY...
- Thomson Reuters StreetEvents
Q4 2023 Summit Therapeutics Inc Earnings Call
Q4 2023 Summit Therapeutics Inc Earnings Call
- Reuters
UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US
I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarket trading. The company will sell its China unit, I-Mab Shanghai, to affiliate Hangzhou Co for up to $80 million, subject to certain regulatory and sales-based milestones. The move makes strategic sense, Cantor Fitzgerald analyst Louise Chen said, adding that the development came as a surprise.
© 2024 Yahoo. All rights reserved.